Editorial: Role of the IL-23/IL-17 Pathway in Chronic Immune-Mediated Inflammatory Diseases: Mechanisms and Targeted Therapies - Institut Pasteur Access content directly
Journal Articles Frontiers in Immunology Year : 2021

Editorial: Role of the IL-23/IL-17 Pathway in Chronic Immune-Mediated Inflammatory Diseases: Mechanisms and Targeted Therapies

Abstract

Editorial on the Research Topic Role of the IL-23/IL-17 Pathway in Chronic Immune-Mediated Inflammatory Diseases: Mechanisms and Targeted Therapies Chronic inflammatory diseases (CID) are clinically heterogeneous conditions that share common inflammatory pathways and derive from aberrant immune responses. The implication of the interleukin-23/interleukin-17 (IL-23/IL-17) axis in several CID is supported by studies in animal models of autoimmune disease (1, 2) and by the genome-wide association studies (GWAS) finding that several of the non-MHC loci genetically linked to Crohn’s disease, psoriasis, and axial spondyloarthritis (axSpA), are associated with genes in this pathway (IL23R, IL12B, IL6R, IL1R2, RORC, RUNX3, TYK2, JAK2, CARD9) (3–5).
Fichier principal
Vignette du fichier
PMID 34630440.pdf (234.48 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

pasteur-03497758 , version 1 (20-12-2021)

Licence

Attribution

Identifiers

Cite

Elisabetta Bianchi, Matteo Vecellio, Lars Rogge. Editorial: Role of the IL-23/IL-17 Pathway in Chronic Immune-Mediated Inflammatory Diseases: Mechanisms and Targeted Therapies. Frontiers in Immunology, 2021, 12, pp.770275. ⟨10.3389/fimmu.2021.770275⟩. ⟨pasteur-03497758⟩

Collections

PASTEUR
33 View
81 Download

Altmetric

Share

Gmail Facebook X LinkedIn More